MSB11022

DRUG3 trials

Sponsors

Fresenius Kabi SwissBioSim GmbH

Conditions

Healthy SubjectsModerate to Severe Plaque PsoriasisModerate to Severe Rheumatoid ArthritisPlaque Type PsoriasisPsoriasis

Phase 1

MSB11022 in Healthy Subjects

CompletedNCT03014947

Fresenius Kabi SwissBioSim GmbHHealthy Subjects

Start: 2014-05-31End: 2014-12-31Updated: 2019-07-01

Phase 3

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT02660580

Fresenius Kabi SwissBioSim GmbHModerate to Severe Plaque Psoriasis, Plaque Type Psoriasis, Psoriasis

Start: 2016-02-16End: 2017-12-18Updated: 2023-12-27

MSB11022 in Moderate to Severe Rheumatoid Arthritis

CompletedNCT03052322

Fresenius Kabi SwissBioSim GmbHModerate to Severe Rheumatoid Arthritis

Start: 2017-01-31End: 2018-08-27Updated: 2019-12-20

Related Papers

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.

2020-12-0134 citations

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.

2019-08-0823 citations

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations